Patient characteristics (N = 1247)
| . | MSD age ≥50 years (n = 721) . | HID age ≤40 years (n = 526) . | P value . |
|---|---|---|---|
| Median follow-up (IQR), mo | 37 (31-42) | 24 (22-26) | <.0001 |
| Patient age, median (range), y | 65 (60-75) | 65 (60-82) | .17 |
| Donor age, median (range), y | 61 (58-65) | 33 (18-40) | <.0001 |
| Year of allo-HCT, median (range) | 2018 (2012-2022) | 2020 (2012-2022) | <.0001 |
| De novo/sAML (%) | 83/17 | 85/15 | .47 |
| Cytogenetics risk, Int/Adv (%) | 70/30 | 72/28 | .39 |
| Sex, M/F (%) | 58/42 | 68/32 | .0006 |
| F donor to M recipient (%) | 33 | 21 | <.0001 |
| CMV+ recipients (%) | 67 | 79 | .0003 |
| Diagnosis to allo-HCT (range), mo | 4.7 (2-22) | 5.3 (2-23) | <.0001 |
| PB/BM (%) | 97/3 | 80/20 | <.0001 |
| MAC/RIC (%) | 18/82 | 22/78 | .06 |
| TCI 1-2/2.5-3.5/4-6 (%) | 56/41/3 | 61/36/2 | .2 |
| ATG/alemtuzumab (%) | 83/17 | 8/0 | <.0001 |
| KPS ≥90 (%) | 67 | 71 | .06 |
| . | MSD age ≥50 years (n = 721) . | HID age ≤40 years (n = 526) . | P value . |
|---|---|---|---|
| Median follow-up (IQR), mo | 37 (31-42) | 24 (22-26) | <.0001 |
| Patient age, median (range), y | 65 (60-75) | 65 (60-82) | .17 |
| Donor age, median (range), y | 61 (58-65) | 33 (18-40) | <.0001 |
| Year of allo-HCT, median (range) | 2018 (2012-2022) | 2020 (2012-2022) | <.0001 |
| De novo/sAML (%) | 83/17 | 85/15 | .47 |
| Cytogenetics risk, Int/Adv (%) | 70/30 | 72/28 | .39 |
| Sex, M/F (%) | 58/42 | 68/32 | .0006 |
| F donor to M recipient (%) | 33 | 21 | <.0001 |
| CMV+ recipients (%) | 67 | 79 | .0003 |
| Diagnosis to allo-HCT (range), mo | 4.7 (2-22) | 5.3 (2-23) | <.0001 |
| PB/BM (%) | 97/3 | 80/20 | <.0001 |
| MAC/RIC (%) | 18/82 | 22/78 | .06 |
| TCI 1-2/2.5-3.5/4-6 (%) | 56/41/3 | 61/36/2 | .2 |
| ATG/alemtuzumab (%) | 83/17 | 8/0 | <.0001 |
| KPS ≥90 (%) | 67 | 71 | .06 |
Adv, adverse; BM, bone marrow; CMV, cytomegalovirus; F, female; Int, intermediate; KPS, Karnofsky performance status; M, male; MAC, myeloablative conditioning; PB, peripheral blood; RIC, reduced-intensity conditioning; sAML, secondary AML; TCI, transplant conditioning intensity.